Takeda Pharmaceutical International, a Zurich-based wholly owned subsidiary of Takeda Pharmaceutical Company, has completed construction at its pharmaceutical manufacturing facility in Yaroslavl, Russia.

The company has invested approximately $97 million in the 24,000 square meter production plant, which is expected to be fully operational by 2014. The facility will enable Takeda to meet demand in Russia, initially producing Cardiomagnyl, Actovegin and calcium tablets. It will also lead to creation of around 200 positions for highly qualified managers and technical staff.

The plant was constructed on time and on budget to local and international GMP standards and adheres to the latest safety and environmental standards. It will have the initial capacity to manufacture 90 million sterile ampoules and more than 2 billion tablets per year. Liquid sterile production includes solution preparation, washing of ampoules, sterilization, filling, inspection and packaging. Solid production will encompass all stages, from weighing, mixing and granulation through compression, coating and packaging.

“The completion of this ambitious project further demonstrates Takeda’s transition into a truly global business, and strategic investment into key emerging markets such as Russia is a major part of this strategy,” said Yasuchika Hasegawa, president and CEO of Takeda Pharmaceutical Company. “Russia is our largest emerging market in terms of revenues and is expected to contribute significantly to our growth over the next few years. The Yaroslavl facility will enable us to provide locally produced pharmaceutical products to patients and clinicians, as well as bringing significant benefits to the Yaroslavl and Russian economy.”